Decrease of valproate-induced hyperammonemia in normal subjects by lipid ingestion.
Sodium valproate (VPA), a branched short-chain fatty acid, always causes a hyperammonemia of renal origin in fasting man. The intake of medium-length, straight-chain fatty acids abolishes the VPA-induced hyperammonemia, and VPA free fraction increases concomitantly. Accordingly, fatty acids could be useful in preventing and treating hyperammonemia-accompanied stuporous states which are complications of VPA medication.
D000641:Ammonia / Q000097:blood*; D004041:Dietary Fats / Q000627:therapeutic use*; D005227:Fatty Acids / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced* / Q000178:diet therapy; D008297:Male; D014635:Valproic Acid / Q000037:antagonists & inhibitors* / Q000097:blood
D004041:Dietary Fats; D005227:Fatty Acids; D014635:Valproic Acid; D000641:Ammonia